Why the study?
Does radionuclide angiocardiography detect early myocardial damage in patients receiving anthracyclines?
Does radionuclide angiocardiography detect early myocardial damage in patients receiving anthracyclines?
Radionuclide angiocardiography indices of early diastolic function (1/3 PFR/EDC and 1/3 FF) can detect silent myocardial damage induced by anthracyclines before LVEF declines.
Diastolic indices may detect early anthracycline damage before LVEF decline; hypothesis-generating and should not yet change practice.
For the early detection of myocardial damage associated with anthracycline therapy, electrocardiography, echocardiography, and radionuclide angiocardiography were used to assess cardiac function in 37 patients receiving anthracyclines (ie, adriamycin and daunorubicin at a total dose of 100-2,030 mg/m2). None of the patients developed clinical congestive heart failure. There were no significant changes of electrocardiographic and echocardiographic parameters after anthracycline administration. The left ventricular ejection fraction did not change significantly on radionuclide angiocardiography. However, the 1/3 peak filling rate (PFR) corrected by the end-diastolic count (EDC) (1/3 PFR/EDC) and the 1/3 filling fraction (1/3 FF), the indices of early diastolic function, showed a significant decrease. These findings suggest that the 1/3 PFR/EDC and 1/3 FF determined by radionuclide imaging are useful for detecting silent myocardial damage induced by anthracyclines.
No takes yet. Share an insight, caveat, or question.
Suzuki et al. (1999) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: